Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Core Insights - Standard BioTools Inc. announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to analyze 100,000 plasma samples, highlighting its strategic position in the biobank segment and its role in global health initiatives [1][2] Company Overview - Standard BioTools is a leader in population proteomics, with the SomaScan platform being utilized in over 30 biobank studies globally, including three major studies this year totaling nearly 160,000 samples [4] - The company provides essential next-generation technologies that assist biomedical researchers in developing better medicines faster, focusing on oncology, immunology, and immunotherapy [7] Industry Context - The PRECISE-SG100K initiative aims to transform healthcare in Singapore by leveraging data-driven solutions to improve patient outcomes, drawing on a multi-ethnic population and extensive health insights [3][10] - Population proteomics studies are generating new datasets that enhance understanding of protein expression dynamics, revealing insights into gene-to-protein correlations and new therapeutic targets [6]